Ultrasensitive Circulating Tumor DNA Improves NSCLC Detection

Foresight Diagnostics Logo

JUN 13, 2024

Ultrasensitive circulating tumor DNA (ctDNA) detection appears to improve the clinical sensitivity of minimal residual disease (MRD) at key landmarks in early stage non-small cell lung cancer (NSCLC), researchers reported at the 2024 ASCO Annual Meeting.

“PhasED-Seq detected MRD at levels below one ppm and was associated with significantly better outcomes, revealing potential benefits of adjuvant therapy in patients with MRD+. This suggests that ultrasensitive MRD detection is promising for use in risk-adapted trials in early stage NSCLC,” James M. Isbell, MD, MSCI, and colleagues wrote in the abstract of their poster presentation.

Read the full article on physiciansweekly.com

Share this page on social

Ready to get started? See what Samba can do for you.